Author: WorkCompAcademy

A plastic surgeon in Beverly Hills, along with his son, medical practices and billing company, have agreed to pay $23.9 million to resolve allegations that they violated the False Claims Act by submitting or causing the submission of false claims to both Medicare and Medicaid.

The settlement resolves allegations that Dr. Joel Aronowitz; Daniel Aronowitz; Joel A. Aronowitz, M.D., a medical corporation; Tower Multi-Specialty Medical Group; Tower Wound Care Center of Santa Monica, Inc.; Tower Outpatient Surgery Center, Inc.; and Tower Medical Billing Solutions falsified the place of service for skin grafts and billed multiple times for single-use skin substitute products.

The United States contends that the settling parties manipulated the place of service code on claims for skin grafts to fraudulently maximize reimbursement from Medicare and Medicaid. The United States further contends that Dr. Aronowitz failed to properly dispose of unused portions of single-use skin graft materials and, instead, used them in later procedures involving other Medicare and Medicaid beneficiaries, resulting in thousands of instances of double billing.

In connection with the settlement, the United States Department of Health and Human Services, Office of Inspector General (HHS OIG), negotiated the voluntary exclusion of Dr. Aronowitz and Tower Multi-Specialty Medical Group from Medicare, Medicaid, and all other federal health care programs for a period of 15 years. Daniel Aronowitz will be excluded for three years.

Medicaid is funded jointly by the states and the federal government. The state of California paid for a portion of the Medicaid claims at issue and will receive a total of approximately $497,619 from the settlement.

The civil settlement includes the resolution of claims brought under the qui tam, or whistleblower, provisions of the False Claims Act by parties that worked for Dr. Aronowitz and his associated medical practices and businesses: TDP, a billing company; Dr. Jason Morris, a podiatrist; and Harold Bautista, a billing department employee.

Under the qui tam provisions, a private party can file an action on behalf of the government and receive a portion of any recovery. The civil lawsuits, all of which were filed in federal court in Los Angeles, are captioned: United States ex rel. TDP RCM Servs., LLC v. Aronowitz, et al., United States ex rel. Morris, et al. v. Tower Wound Care Ctr. of Santa Monica, Inc., et al., and United States ex rel. Bautista et al. v. Tower Outpatient Surgery Center, Inc., et al.. The amount to be recovered by the private parties has not been determined.

The resolution obtained in this matter was the result of a coordinated effort between the United States Attorney’s Office in Los Angeles and the United States Justice Department’s Civil Division, Commercial Litigation Branch, Fraud Section. HHS OIG assisted in the investigation.

The matter was handled by Assistant United States Attorney Aaron Ezroj of the Civil Fraud Section and Trial Attorney Lyle Gruby of the Justice Department’s Civil Division. The exclusions of the individuals and entity were negotiated by Senior Counsel Patrice Drew for HHS OIG.

The investigation and resolution of this matter illustrates the government’s emphasis on combating healthcare fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse and mismanagement can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

The claims resolved by the settlement are allegations only and there has been no determination of liability.

In recent panel decisions the WCAB seems to be less forgiving of litigants who assert what seems to be obvious facts in a case, but then do not submit substantial evidence to prove their assertion. The lesson here it to make sure every essential detail needed to win an issue has been meticulously documented and proven at trial.

In this case, Sherrill Claytor was injured on June 12, 2014 while employed as a doctor’s assistant by Alexander T. Latteri, M.D. She treated with Dr. Spencer as her PTP from 2014 to 2019.

On September 3, 2019, Claytor sent State Fund a letter selecting Scott Small, M.D. as her PTP and request to change her PTP. Dr. Small provided treatment to her from 2019 into 2020 and she also continued to receive treatment from Dr. Spencer from July 2019 to at least December 2019 while also treating with Dr. Small.

On June 1, 2020, Claytor sent a letter to SCIF requesting to treat with Dr. Spencer as her PTP again. On June 15, 2020, SCIF replied stating that it ended the contract with Harbor Health Systems as the MPN administrator of the State Fund MPN by Harbor Health effective July 27, 2020. But it also said that “State Fund will allow you to continue your treatment with your current primary treating physician, treating physicians and/or providers after July 27, 2020.”

The matter proceeded to trial on December 1, 2020 with the sole issue identified as: “Can the Applicant resume treatment with Dr. Spencer as the PTP outside of the MPN.” By the F&O, the WCJ found that applicant is permitted to treat with Dr. Curtis Spencer outside of defendant’s medical provider network (MPN).

The State Fund petition for Reconsideration was denied in the panel decision of Sherrill Claytor v SCIF – ADJ11059073 (January 2023).

If an employer has established an MPN, injured workers are generally limited to treating with a physician from within the employer’s MPN. However, if the employer neglects or refuses to provide reasonably necessary medical treatment, whether through an MPN or otherwise, then an injured worker may self-procure medical treatment at the employer’s expense.

The Appeals Board has held en banc that “a defendant may satisfy its obligation under Labor Code section 4600 to provide reasonable medical treatment by transferring an injured worker into an MPN in conformity with applicable statutes and regulations regardless of the date of injury or the date of an award of future medical treatment.” (Babbitt v. Ow Jing (2007) 72 Cal.Comp.Cases 70, 71 (Appeals Board en banc).)

Here SCIF argues that Claytor was brought back into the MPN when she selected Dr. Small as her PTP and thus, she may not now choose a non-MPN physician absent a denial of care.

To this argument the panel noted that if “Dr. Small is a member of defendant’s MPN (whether the old or new MPN), there may be a viable argument that applicant voluntarily returned herself to the MPN by selecting Dr. Small as her PTP and she may not now choose a PTP outside the MPN absent a denial of care. However, this conclusion presumes that Dr. Small is actually in the MPN, a fact that applicant has not conceded and is not supported by substantial evidence in the record.”

“We do not presume Dr. Small is in the MPN based solely on defendant’s assertion that he is a member of it.“

Defendant contends that applicant’s September 3, 2019 letter selecting Dr. Small as her PTP “should be sufficient for a finding that Dr. Small was in State Fund’s MPN at the time.”

“We disagree that applicant’s September 3, 2019 letter is sufficient to show that Dr. Small is in the MPN.” “Put simply, there is not substantial evidence showing that applicant was treating within the MPN when she requested to have Dr. Spencer resume his role as PTP. There is also no evidence in the record that defendant objected to applicant’s June 1, 2020 request to have Dr. Spencer act as her PTP again.”

“There is substantial evidence to show years of treatment outside the MPN and no effective transfer of care returning applicant to treatment within the MPN. Under these circumstances, applicant is entitled to resume treatment with her non-MPN physician, Dr. Spencer, as her PTP.“

However, the WCJ expressly found that defendant may return applicant to the MPN by complying with the statutory and regulatory requirements for transfer of care and continuity of care policies. Defendant must comply with the process outlined in AD Rule 9767.9(f) for transferring care.

The transfer of care provisions in Rule 9767.9(f) require defendant to make a determination regarding whether applicant’s condition satisfies – or fails to satisfy – one of the four conditions set forth in subsections (e)(1)-(4). This section requires that defendant determine whether applicant has a condition which would allow her to complete treatment with her PTP.

Furthermore, the regulation requires that defendant notify applicant of its determination regarding completion of care. This notification must also be sent to applicant’s PTP, be in English and Spanish, and use layperson’s terms to the maximum extent possible.

GPT stands for Generative Pre-trained Transformer (GPT), a type of language model that uses deep learning to generate human-like, conversational text.

ChatGPT is an artificial intelligence chatbot developed by OpenAI and released in November 2022. It works by gathering data (e.g.from the internet) written by people and using computing predictions to answer questions and queries inputted by the user. The latest version is GPT-4, which has been adopted by a number of companies, including Microsoft, Google, Facebook, Amazon, and IBM.

The technology is now the tool of choice for the intelligent digital worker that can work across pieces of software and data stores to automate increasingly sophisticated processes.

Earlier this year. it was reported that GPT-4 successfully passed the Uniform Bar Exam for prospective attorneys, with flying colors in every field and test segment, even outperforming the average human student.

And the technology is now on the doorstep of workers’ compensation claims.

Sedgwick has launched Sidekick, which they say is an industry-first integration using Microsoft’s OpenAI tools and services to give claims professionals an advantage in their daily work.

The application, which leverages OpenAI’s GPT-4 technology, is Sedgwick’s first use case of GPT. Designed for internal use within the company’s secure Azure environment,

Sidekick will allow Sedgwick colleagues to explore the impact of generative artificial intelligence (AI) performance and natural language processing on day-to-day tasks.

It joins Sedgwick’s existing set of tools powered by AI – including smart.ly, mySedgwick and viaOne – in transforming the way people interact with and leverage technology for better outcomes.

“Innovation is in our DNA,” said Mike Arbour, CEO of Sedgwick. “Sedgwick is proud to be first in the industry to utilize GPT not only for improved claims documentation, but to show how much we value the human touch. Sidekick is designed to supercharge our claims professionals – to help them move through some of the administrative tasks of claims management at speeds never before possible. Automating important but routine aspects of our work processes will help them gain value from information more quickly, relay it back to our clients efficiently, and dedicate more time to the people whose care is entrusted to them.”

As a first step, Sedgwick is integrating its industry-leading platforms already in use with Sidekick’s AI capabilities to promote claims document summarization, data classification and analysis. Initial examples of how colleagues can effectively work alongside Sidekick include:

– – Scanning PDF documents to produce automated content summaries, and easily adding the highlights to the appropriate claim file.
– – Utilizing the application to quickly uncover key data to help complete tasks and meaningfully impact claims.

Sedgwick anticipates future iterations of the application may be able to produce entire claim summaries, identify risk factors on individual claims and programs, explore emerging data trends, and more.

“As part of Sedgwick’s people first, tech forward and data driven approach to claims and productivity challenges, we are focused on three things,” said Jason Landrum, Sedgwick’s global chief information officer. “Communication and transforming the way we engage with people through different channels; automation of our processes and digitization of our tools; and innovation to leverage the latest advances in technology strategically but also securely. With Sidekick, we are leveraging evolving GPT technology for good – empowering the people who impact claims and finding ways to boost their engagement, job satisfaction and performance.”

With 2,000 dedicated IT resources and data scientists, Sedgwick says that it delivers superior technology-enabled solutions to many of the world’s premier employers and insurers. They say the company’s capabilities and systems are unparalleled, supporting virtually any kind of loss or claims program and prompting outstanding results: higher return on investment, decreased litigation, better understanding of customer concerns, faster resolution and improved overall satisfaction.

The Department of Labor’s Office of Workers’ Compensation Programs (OWCP) provides workers’ compensation coverage to approximately 2.6 million federal and postal workers through the Federal Employees’ Compensation Act (FECA) program.

Back In Fiscal Year (FY) 2015 and FY 2016, a sharp increase in pharmaceutical spending for the FECA program raised concerns. Subsequent Office of Inspector General work found OWCP had not done enough to ensure it paid the best prices for prescription drugs, specifically noting the lack of a pharmacy benefit manager to help contain costs and the failure to determine if alternative prescription drug pricing methodologies would be more competitive.

In response, OWCP said it took a number of actions to reduce pharmaceutical spending, including implementing controls on prescriptions for compounded drugs and for opioids. According to data provided by OWCP, it significantly decreased total compounded drug spending from almost $256 million in FY 2016 to less than $176,000 in FY 2020 and reduced opioid spending from over $86 million in FY 2016 to approximately $29 million in FY 2020.5

However, the Office of Inspector General remained concerned about OWCP’s ability to effectively manage the cost, as well as the use, of pharmaceuticals in the FECA program.

Given these concerns, U.S. Office of Inspector General recently contracted with the independent certified public accounting firm of Harper, Rains, Knight & Company, P.A. (HRK) to conduct an audit to determine if OWCP had indeed effectively managed pharmaceutical spending in the FECA program since the 2015-2016 audit.

To answer this question, HRK’s audit included: analyzing 6 years of pharmaceutical data covering Fiscal Year 2015 through Fiscal Year 2020; interviewing OWCP management; reviewing OWCP policies, procedures, and other documentation; and comparing the FECA program to industry best practices and other workers’ compensation programs.

The March 2023 Office of Inspector General audit report found that OWCP did not effectively manage pharmaceutical spending in the FECA program from Fiscal Year 2015 through Fiscal Year 2020. Specifically, OWCP did not pay the best available prices for prescription drugs. HRK identified up to $321.26 million in excess spending during the audit period.

In addition, OWCP did not effectively monitor pharmaceutical policy changes to ensure implementation, resulting in claimants receiving thousands of inappropriate prescriptions and potentially lethal drugs, including 1,330 prescriptions for fast-acting fentanyl after issuing a policy that restricted its use.

HRK also found OWCP failed to timely identify and address emerging issues and did not perform sufficient oversight of prescription drugs that are highly scrutinized and rarely covered in workers’ compensation programs. As a result, OWCP spent hundreds of millions of dollars on drugs that may not have been necessary or appropriate for FECA claimants.

Finally, HRK found OWCP lacked sufficient clinical expertise and guidelines to ensure appropriate pharmaceutical decisions, which could negatively impact claimants’ health, recovery, and return to work.

Remarkably the current audit noted that “Health Affairs, a peer-reviewed journal of health policy that has been cited by government officials and national media, reported that prescription drug rebates can sometimes reach 50 percent or more of list price and total Medicare Part D drug spending offset by rebates on brand name drugs in 2018 was 25 percent.”

“Even though incorporating rebates can result in substantial savings, OWCP indicated it did not incorporate prescription drug manufacturer rebates in the FECA pharmaceutical program. According to OWCP officials, the FECA program never had a mechanism, or a contract, to incorporate rebates for pharmacy expenditures during the audit period.”

On the topic of appropriate prescriptions, the new audit continued to say that “OWCP issued significant policy and process changes related to claimant prescriptions prior to and during the audit period. Although these changes were intended to improve claimant safety and save costs, OWCP did not ensure the changes were properly implemented.”

“This occurred because OWCP did not effectively monitor its bill pay vendor, who was responsible for implementing these changes. As a result, OWCP allowed claimants to receive thousands of inappropriate prescriptions and potentially lethal drugs, which could have caused serious harm to claimants.”

“For example, OWCP paid for more than 98 percent (1,330 of 1,348) of prescriptions for fast-acting fentanyl, a potentially lethal and extremely addictive drug, without evidence of required cancer diagnoses.”

HRK made 10 recommendations to OWCP to strengthen management of pharmaceuticals in the FECA program, specifically regarding: evaluating alternate pricing methodologies, ensuring implementation of and adherence to policies, identifying emerging issues by developing and implementing an ongoing pharmaceutical monitoring program, ensuring sufficient clinical expertise among FECA staff, and using evidence-based clinical guidelines to inform prescription drug coverage policies.

OWCP generally agreed with the latest recommendations.

Proposed legislation would enact important changes to hold dangerous doctors more accountable in California, but, according to Consumer Watchdog the proposal excludes crucial reforms that will continue threaten patient safety.

Under current law, the Medical Board of California is comprised of 15 members: eight physicians and seven public members. All eight professional members and five of the public members are appointed by the Governor. One public member of the Board is appointed by the Senate Committee on Rules and one public member is appointed by the Speaker of the Assembly.

The bill, SB 815,creates a public member majority on the Medical Board by adding two additional public members, a top priority of patient advocates, however advocates say the proposed law fails to mandate patients have rights in the enforcement process or receive timely information about their doctors. The legislation under consideration is the Medical Board’s sunset review bill and must be passed this year.

The bill creates a Complainant Liaison Unit at the Medical Board to interact with members of the public, but does not give people who file a complaint about patient harm rights in the enforcement process. That means, for example, the Board does not have to interview the patient who was harmed, or the loved ones of a patient who died, before closing their complaint. The bill also does not address advocates’ call for greater disclosure of doctors’ records online and in person, so patients will remain in the dark if their doctor has harmed other patients.

The bill does however propose several important reforms that patient advocates have championed and support, said Consumer Watchdog, including: Changing the balance of power on the board by giving it more public than doctor members; reducing the standard of proof in doctor discipline cases to match that used by 41 other state boards and reduce the time and cost of investigations; and increasing the doctor licensing fees that fund the Board so it can address staffing shortages and reduce case timelines that have crippled accountability.

The Board is required under current case law, (Ettinger v. Board of Medical Quality Assurance (1982) 135 Cal.App.3d 853, 856), to obtain “clear and convincing proof to a reasonable certainty.” This is a higher burden of proof than in 41 other jurisdictions throughout the U.S. states and territories, which generally apply a “preponderance of evidence’ standard.”

The proposed new law specifies that the standard of proof required to obtain an order on a statement of issues or accusation for a violation that would result in license suspension or revocation shall be a clear and convincing evidence standard and a preponderance of the evidence standard for any other violation.

And to facilitate the investigation process, the proposed law requires, when requested by an authorized officer of the law or by an authorized MBC representative, the owner, corporate officer, or manager of an entity licensed by the Board of Pharmacy to provide records within 3 days of when the request was made. And the proposal also requires MBC licensees to participate in an interview no later than 30 calendar days after being notified when the licensee is under investigation.

Under current law, MBC’s Central Complaint Unit (CCU) receives and triages all complaints. If it appears that a violation may have occurred, the complaint is transferred either to the DCA’s Division of Investigation, Health Quality Investigation Unit (HQIU), which includes sworn peace officers, or to MBC’s own Complaint Investigation Office (CIO), which is comprised of non-sworn special investigators.

Investigators investigate the complaint and, if warranted, refer the case for disciplinary action. MBC’s Discipline Coordination Unit processes all disciplinary documents and monitors cases that have been referred for formal discipline to the Office of the Attorney General (OAG), which serves as MBC’s prosecuting attorney.

If a licensee or registrant is placed on probation, MBC’s probation unit monitors the individual while they are on probation to ensure they are complying with the terms and conditions of probation. The Probation Unit is comprised of inspectors who are located throughout the state, housed within various field offices. Having inspectors throughout the state helps eliminate excess travel and enables probationers to have face-to-face meetings with the inspectors for monitoring purposes.

“We applaud Senator Roth for proposing reforms in this bill that will increase doctor accountability, including adding two public members to the Board, but without additional changes dangerous doctors will escape investigation and patients will continue to be harmed,” said Carmen Balber, executive director of Consumer Watchdog.